PaxMedica Inc [NASDAQ: PXMD] jumped around 1.45 points on Tuesday, while shares priced at $4.50 at the close of the session, up 47.54%. The company report on November 7, 2023 at 8:00 AM that PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal.
PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the publication of research findings in the Annals of General Psychiatry. The research, led by Chief Medical Officer Dr. David Hough, along with a team of renowned co-authors specializing in Autism Spectrum Disorder (ASD), the research explores the potential of low-dose suramin intravenous infusions as an ASD treatment.
This comprehensive, 14-week randomized, double-blind, placebo-controlled study enrolled 52 boys aged 4-15 years with moderate to severe ASD. The primary focus of the study was to evaluate the efficacy and safety of suramin intravenous infusions, with the 10 mg/kg suramin arm demonstrating promising results in the improvement of core symptoms. Notably, the study revealed statistically significant improvements in the Clinical Global Impressions-Improvement (CGI-I) scale among the 10 mg/kg arm compared to the placebo group.
PaxMedica Inc stock is now -86.96% down from its year-to-date (YTD) trading value. PXMD Stock saw the intraday high of $10.26 and lowest of $4.37 per share. The company’s 52-week high price is 69.19, which means current price is +80.00% above from all time high which was touched on 02/03/23.
Compared to the average trading volume of 139.45K shares, PXMD reached a trading volume of 35124125 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about PaxMedica Inc [PXMD]?
The Average True Range (ATR) for PaxMedica Inc is set at 1.35 The Price to Book ratio for the last quarter was 1.80, with the Price to Cash per share for the same quarter was set at 3.04.
How has PXMD stock performed recently?
PaxMedica Inc [PXMD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 42.86. With this latest performance, PXMD shares gained by 31.69% in over the last four-week period, additionally sinking by -82.11% over the last 6 months – not to mention a drop of -84.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PXMD stock in for the last two-week period is set at 54.00, with the RSI for the last a single of trading hit 61.06, and the three-weeks RSI is set at 49.06 for PaxMedica Inc [PXMD]. The present Moving Average for the last 50 days of trading for this stock 4.76, while it was recorded at 3.17 for the last single week of trading, and 20.65 for the last 200 days.
PaxMedica Inc [PXMD]: Deeper insight into the fundamentals
When it comes to the capital structure of this company, PaxMedica Inc [PXMD] has a Total Debt to Total Equity ratio set at 307.44. Additionally, PXMD Total Debt to Total Capital is recorded at 75.46, with Total Debt to Total Assets ending up at 15.17.
Reflecting on the efficiency of the workforce at the company, PaxMedica Inc [PXMD] managed to generate an average of -$2,960,353 per employee.PaxMedica Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.12 and a Current Ratio set at 2.12.
Insider trade positions for PaxMedica Inc [PXMD]
The top three institutional holders of PXMD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in PXMD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in PXMD stock with ownership which is approximately 5.7994%.